NASDAQ$DNLI
Denali Therapeutics Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Denali Therapeutics experienced a net loss, decreased collaboration revenue, and increased research and development expenses.
Denali Therapeutics reported a net loss for the quarter ended December 31, 2019, compared to net income for the same period in 2018. There was a decrease in collaboration revenue and an increase in research and development expenses.
- Net loss of $54.0 million for the quarter ended December 31, 2019, compared to net income of $77.5 million for the quarter ended December 31, 2018.
- Collaboration revenue was $4.7 million for the quarter ended December 31, 2019, compared to $125.7 million for the quarter ended December 31, 2018.
- Total research and development expenses were $51.6 million for the quarter ended December 31, 2019, compared to $39.9 million for the quarter ended December 31, 2018.
- Cash, cash equivalents, and marketable securities were $455.2 million as of December 31, 2019.
Headline financials
Revenue & EPS history
Denali Therapeutics · Revenue · Quarterly
$4.67M
Forward guidance
Denali expects key milestones in 2020, including advancing its LRRK2 program into late stage clinical testing and establishing clinical biomarker proof-of-concept with its first large molecule program, ETV:IDS (DNL310) in Hunter syndrome.
Tailwinds
- Advancing LRRK2 program into late stage clinical testing.
- Establishing clinical biomarker proof-of-concept with ETV:IDS (DNL310) in Hunter syndrome.
- Initiating a Phase 1/2 study for DNL310 in Hunter syndrome patients in the first half of 2020.
- Positive results from a Phase 1b study with DNL201 in patients with Parkinson’s disease.
- Commenced dosing of its small molecule activator of EIF2B, DNL343, in healthy volunteers.
Headwinds
- Early stages of clinical drug development.
- Ability to complete the development and, if approved, commercialization of its product candidates.
- Risk of the occurrence of any event, change or other circumstance that could give rise to the termination of Denali’s collaboration agreements.
- Dependence on successful development of its BBB platform technology.
- Ability to conduct or complete clinical trials on expected timelines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
44%
14 / 32 earnings
Positive
+19.7%
Q4 2023
Best reaction
-13.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -1.0% | -4.9% | -15.2% | |
| Q3 2025 | -3.2% | +18.1% | +34.0% | |
| Q1 2025 | +1.0% | -0.9% | +6.1% | |
| Q4 2024 | -1.5% | -15.6% | -21.8% | |
| Q3 2024 | +7.1% | +14.2% | -10.0% | |
| Q2 2024 | -10.3% | -9.7% | +0.3% | |
| Q1 2024 | +10.3% | +6.8% | +24.3% | |
| Q4 2023 | +19.7% | +23.5% | +21.5% | |
| Q3 2023 | -2.7% | -21.8% | -9.7% | |
| Q2 2023 | -5.2% | -7.6% | -7.3% | |
| Q1 2023 | +3.0% | +5.4% | +16.1% | |
| Q4 2022 | +4.8% | +7.3% | -10.9% | |
| Q3 2022 | -7.8% | -10.3% | +6.2% | |
| Q2 2022 | +4.6% | +6.6% | -17.5% | |
| Q1 2022 | -13.7% | -14.0% | -8.5% | |
| Q4 2021 | -2.8% | -7.8% | -1.9% | |
| Q3 2021 | +3.5% | -0.4% | -19.9% | |
| Q2 2021 | +3.5% | +4.6% | +6.6% | |
| Q1 2021 | -8.0% | -10.2% | +5.5% | |
| Q4 2020 | +7.5% | -5.8% | -17.2% | |
| Q3 2020 | +5.2% | +16.3% | +40.8% | |
| Q2 2020 | +6.1% | -5.4% | -2.5% | |
| Q1 2020 | -5.5% | -5.7% | +2.6% | |
| Q4 2019 | -8.6% | -10.0% | -12.5% | |
| Q3 2019 | -6.1% | -10.1% | +10.5% | |
| Q2 2019 | +0.6% | +5.4% | -4.2% | |
| Q1 2019 | -4.8% | -11.4% | -18.9% | |
| Q4 2018 | +11.7% | +12.0% | +26.4% | |
| Q3 2018 | -4.0% | -0.6% | +12.7% | |
| Q2 2018 | -0.5% | -0.7% | +17.0% | |
| Q4 2017 | -4.8% | -5.1% | +2.2% | |
| Q1 2018 | -8.8% | -8.0% | -12.4% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro